Vascular Endothelial Growth Factor and Its Soluble Receptor in Systemic Lupus Erythematosus Patients

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Dec 23

PMID 36551311

Authors

Fuensanta Gomez-Bernal

Yolanda Fernandez-Cladera

Juan Carlos Quevedo-Abeledo

Maria Garcia-Gonzalez

Agustin F Gonzalez-Rivero

Antonia de Vera-Gonzalez

Candelaria Martin-Gonzalez

Miguel A Gonzalez-Gay

Ivan Ferraz-Amaro

Affiliations

Soon will be listed here.

Abstract

Vascular endothelial growth factor (VEGF) is a major regulator of physiological and pathological angiogenesis. Its soluble receptor (sVEGFR) is a potent VEGF antagonist. Systemic lupus erythematosus (SLE) is an autoimmune disease with a diverse array of clinical manifestations that affect virtually any organ. We aimed to analyze the relationship of VEGF and sVEGFR with SLE disease-related features including disease activity, damage, and severity. Serum levels of VEGF165 isoform and sVEGFR (receptor 1) were assessed in 284 well-characterized patients with SLE. Linear regression analysis was performed to analyze the relationship of disease characteristics with both VEGF and sVEGFR. Patients with a disease damage index (SLICC score) equal to or greater than 1 had significantly elevated serum levels of VEGF and sVEGFR. Regarding disease-specific features, musculoskeletal manifestations were the disease feature most commonly associated with the upregulation of both VEGF and sVEGFR. SLE disease damage is associated with higher levels of VEGF and sVEGFR.

Citing Articles

Systemic Lupus Erythematous: Gene Polymorphisms, Epigenetics, Environmental, Hormonal and Nutritional Factors in the Consideration of Personalized Therapy.

Wais N, Agrawal D Arch Intern Med Res. 2025; 7(4):331-340.

PMID: 39866364 PMC: 11759484. DOI: 10.26502/aimr.0188.

Psoriasis and Lupus Erythematosus-Similarities and Differences between Two Autoimmune Diseases.

Fijalkowska A, Wojtania J, Wozniacka A, Robak E J Clin Med. 2024; 13(15).

PMID: 39124628 PMC: 11312967. DOI: 10.3390/jcm13154361.

Update of Potential Biomarkers in Risk Prediction and Monitoring of Atherosclerosis in Systemic Lupus Erythematosus to Prevent Cardiovascular Disease.

Blachut D, Przywara-Chowaniec B, Tomasik A, Kukulski T, Morawiec B Biomedicines. 2023; 11(10).

PMID: 37893187 PMC: 10604001. DOI: 10.3390/biomedicines11102814.

References

Corrales A, Parra J, Gonzalez-Juanatey C, Rueda-Gotor J, Blanco R, Llorca J . Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2013; 72(11):1764-70. DOI: 10.1136/annrheumdis-2013-203688. View

Takano S, Uchida K, Inoue G, Matsumoto T, Aikawa J, Iwase D . Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis. BMC Musculoskelet Disord. 2018; 19(1):204. PMC: 6020436. DOI: 10.1186/s12891-018-2127-2. View

Colombo B, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G . Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev. 2008; 8(4):309-15. DOI: 10.1016/j.autrev.2008.10.002. View

Ferrara N . Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009; 29(6):789-91. DOI: 10.1161/ATVBAHA.108.179663. View

Mok C, Lau C . Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003; 56(7):481-90. PMC: 1769989. DOI: 10.1136/jcp.56.7.481. View

Dvorak H, Nagy J, Feng D, Brown L, Dvorak A . Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999; 237:97-132. DOI: 10.1007/978-3-642-59953-8_6. View

Prieto-Pena D, Remuzgo-Martinez S, Genre F, Ocejo-Vinyals J, Atienza-Mateo B, Munoz-Jimenez A . Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. Clin Exp Rheumatol. 2022; 40(4):727-733. DOI: 10.55563/clinexprheumatol/8mku9c. View

Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M . The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(3):363-9. DOI: 10.1002/art.1780390303. View

Ferrara N . Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl). 1999; 77(7):527-43. DOI: 10.1007/s001099900019. View

10.

Shibuya M . Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006; 9(4):225-30. DOI: 10.1007/s10456-006-9055-8. View

11.

Katz J, Senecal J, Rivest C, Goulet J, Rothfield N . A simple severity of disease index for systemic lupus erythematosus. Lupus. 1993; 2(2):119-23. DOI: 10.1177/096120339300200210. View

12.

Cook K, Figg W . Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin. 2010; 60(4):222-43. PMC: 2919227. DOI: 10.3322/caac.20075. View

13.

Dabravolski S, Khotina V, Omelchenko A, Kalmykov V, Orekhov A . The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets. Int J Mol Sci. 2022; 23(2). PMC: 8781560. DOI: 10.3390/ijms23020931. View

14.

Chung A, Ferrara N . Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011; 27:563-84. DOI: 10.1146/annurev-cellbio-092910-154002. View

15.

Kuryliszyn-Moskal A, Klimiuk P, Sierakowski S, Ciolkiewicz M . Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities. Arch Immunol Ther Exp (Warsz). 2007; 55(3):179-85. PMC: 2765643. DOI: 10.1007/s00005-007-0017-7. View

16.

Prager G, Breuss J, Steurer S, Mihaly J, Binder B . Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood. 2003; 103(3):955-62. DOI: 10.1182/blood-2003-07-2214. View

17.

Hochberg M . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9):1725. DOI: 10.1002/art.1780400928. View

18.

Gladman D, Ibanez D, Urowitz M . Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29(2):288-91. View

19.

Goldman C, Kendall R, Cabrera G, Soroceanu L, Heike Y, Gillespie G . Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A. 1998; 95(15):8795-800. PMC: 21156. DOI: 10.1073/pnas.95.15.8795. View

20.

Kim H, Kim K, Kim B, Cho M, Lee S . The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. PLoS One. 2015; 10(4):e0124909. PMC: 4404365. DOI: 10.1371/journal.pone.0124909. View